Atlas Trials

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Clinical trial NCT03061214 · COMPLETED

Trial details

NCT number
NCT03061214
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
DiabetesDiabetes Mellitus, Type 2
Start date
2017-08-28
Primary completion
2019-03-14
Enrollment
868

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.